Sema is a glucagon-like peptide 1 (GLP-1) receptor agonist. GLP-1 is a hormone produced in the gut. It is released in response to food, prompting the release of insulin as well as a reduction in appetite. In the case of people with type 2 diabetes, it acts to slow digestion and so stimulates increased production of natural insulin. Sema does not provide insulin from external sources (injection or oral insulin). For people who have been classified as overweight (with BMI between 20 and 23 plus associated medical conditions) or obese (with BMI greater than 23), sema may be prescribed off-label as a weight-loss treatment along with appropriate diet controls and exercise. NOTE: *we do not provide Bacterialstatic Water or Injectable Solution to Reconstitute - You can find this on Amazon** Disclaimer: For Research Purposes Only This content is provided strictly for research purposes and does not constitute an endorsement or recommendation for the non-laboratory application or improper handling of peptides designed for research. The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use in humans. Peptides described here are solely for use in structured scientific study by authorized individuals. We advise consulting with research experts, medical practitioners, or legal counsel prior to any decisions about obtaining or utilizing these peptides. The expectation of responsible, ethical utilization of this information for legitimate investigative and scholarly objectives is paramount. This notice is dynamic and governs all provided content on research peptides.